DP
BCYC

Diadema Partners’s Bicycle Therapeutics BCYC Stock Holding History

Diadema Partners’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.96M Sell
462,724
-13,700
-3% -$62.8K 0.25% 79
2026
Q1 		$2.21M Buy
+476,424
New +$2.72M 0.38% 56

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Diadema Partners's BCYC Position: Q2 2026 in Review

Diadema Partners reduced its Bicycle Therapeutics (BCYC) stake by 2.9% in Q2 2026, selling an estimated $62.8K and leaving 462,724 shares worth $1.96M. The position accounts for 0.25% of the portfolio, ranked #79.

Diadema Partners first reported a position in BCYC in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.21M in Q1 2026. 104 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • Diadema Partners held 462,724 shares of Bicycle Therapeutics worth $1.96M as of Q2 2026.
  • Diadema Partners sold 13,700 Bicycle Therapeutics shares in Q2 2026, an estimated $62.8K.
  • Bicycle Therapeutics made up 0.25% of Diadema Partners's portfolio in Q2 2026, its #79 holding.
  • Diadema Partners first reported a position in Bicycle Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Diadema Partners's Bicycle Therapeutics position peaked at $2.21M in Q1 2026.
  • 104 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.